Exposure to lysosomotropic amines and protease inhibitors retard corneal endothelial cell migration along the natural basement membrane during wound repair

Experimental Cell Research

Volumn 246, Issue 1, 1999, Pages 233-242

  Gordon, Sheldon R ^a   DeMoss, James ^a  

^a OAKLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,10 PHENANTHROLINE; ANTIPAIN; CHLOROQUINE; LEUPEPTIN; LYSOSOMOTROPIC AMINE DERIVATIVE; METALLOPROTEINASE INHIBITOR; METHYLAMINE; PHOSPHORAMIDON; PROPYLAMINE; PROTEINASE INHIBITOR; SOYBEAN TRYPSIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORNEA ENDOTHELIUM; DESCEMET MEMBRANE; DOSE TIME EFFECT RELATION; DRUG MECHANISM; ENDOTHELIUM CELL; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; RAT; WOUND HEALING;

ANIMALIA; GLYCINE MAX;

EID: 0033540265     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1998.4298     Document Type: Article

References (81)

1. Gordon S. R., Rothstein H. Studies on corneal endothelial growth and repair. I. Microfluorometric and autoradiographic analyses of DNA synthesis, mitosis and amitosis following freeze injury. Metab. Ophthamol. 2:1978;57-63.
2. Joyce N. C., Navon S. E., Roy S., Zieske J. D. Expression of cell cycle-associated proteins in human and rabbit corneal endotheliumin situ. Invest. Ophthalmol. Vis. Sci. 37:1996;1566-1575.
3. 33. Tissue Cell. 12:1980;647-659.
4. Tuft S. J., Williams K. A., Coster D. J. Endothelial repair in the rat cornea. Invest. Ophthalmol. Vis. Sci. 27:1986;1199-1204.
5. Gordon S. R., Rothstein H. Studies on corneal endothelial growth and repair. III. Effects of DNA and RNA synthesis inhibitors upon restoration of transparency following injury. Ophthal. Res. 14:1982;195-209.
6. Gordon S. R., Rothstein H., Harding C. V. Studies on corneal endothelial growth and repair. IV. Changes in the surface during cell division as revealed by scanning electron microscopy. Eur. J. Cell Biol. 31:1983;26-33.
7. Matsuda M., Sawa M., Edelhauser H. F., Bartels S. P., Neufield A. H., Kenyon K. R. Cellular migration and morphology in corneal endothelial wound repair. Invest. Ophthalmol. Vis. Sci. 26:1985;443-449.
8. Gordon S. R. Changes in the distribution of extracellular matrix proteins during wound repair in corneal endothelium. J. Histochem. Cytochem. 36:1988;409-416.
9. Sabet M. D., Gordon S. R. Ultrastructural immunocytochemical localization of fibronectin deposition during corneal endothelial wound repair: Evidence for cytoskeletal involvement. Biol. Cell. 65:1989;171-179.
10. Gordon S. R., Staley C. A. Role of the cytoskeleton during injury-induced cell migration in corneal endothelium. Cell Motil. Cytoskel. 16:1990;47-57.
11. Ichijima H., Petroll W. M., Barry P. A., Andrews P. M., Dai M., Cavanagh H. D., Jester J. V. Actin filament organization during endothelial wound healing in the rabbit cornea: Comparison between transcorneal freeze and mechanical scrape injuries. Invest. Ophthalmol. Vis. Sci. 34:1993;2803-2812.
12. Gordon S. R., Buxar R. B. Inhibition of cytoskeletal reorganization stimulates actin and tubulin syntheses during injury-induced cell migration in the corneal endothelium. J. Cell. Biochem. 67:1997;409-421.
13. Kalebic T., Garbisa S., Glaser B., Liotta L. A. Basement membrane collagen: Degradation by migrating endothelial cells. Science. 221:1983;281-283.
14. Grøndahl-Hansen J., Lund L. R., Ralfkiær E., Ottevanger V., Danø K. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J. Invest. Dermatol. 90:1988;790-795.
15. Woessner J. F. Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5:1991;2145-2154.
16. Girad M. T., Matsubara M., Kublin C., Tessier M. J., Cintron C., Fini M. E. Stromal fibroblasts synthesize collagenase and stromelysin during long-term tissue remodeling. J. Cell Sci. 104:1993;1001-1011.
17. Rømer J., Bugge T. H., Pyke C., Lund L. R., Flick M. J., Degen J. L., Danø K. Impaired wound healing in mice with a disrupted plasminogen gene. Nature Med. 2:1996;287-292.
18. Kenagy R. D., Vergel S., Mattsson E., Bendeck M., Reidy M. A., Clowes A. W. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arterioscler. Thromb. Vasc. Biol. 16:1996;1373-1382.
19. Moses M. A., Marikovsky M., Harper J. W., Vogt P., Eriksson E., Klagsbrun M., Langer R. Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound repair. J. Cell. Biochem. 60:1996;379-386.
20. Chan K. Y. Release of plasminogen activator by cultured corneal epithelial cells during differentiation and wound closure. Exp. Eye Res. 42:1986;417-431.
21. Pepper M. S., Vassalli J.-D., Montesano R., Orci L. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J. Cell Biol. 105:1987;2535-2541.
22. Erickson C. A., Isseroff R. R. Plasminogen activator activity is associated with neural crest cell motility in tissue culture. J. Exp. Zool. 251:1989;123-133.
23. Quax P. H. A., Boxman I. L. A., van Kesteren C. A. M., Verheijen J. H., Ponec M. Plasminogen activators are involved in keratinocyte and fibroblast migration in wounded cultures in vitro. Fibrinolysis. 8:1994;221-228.
24. Buisson A.-C., Gilles C., Polette M., Zahm J.-M., Birembaut P., Tournier J.-M. Wound repair-induced expression of stromelysins is associated with the acquisition of a mesenchymal phenotype in human respiratory epithelial cells. Lab. Invest. 74:1996;658-669.
25. Sloane B. F., Dunn J. R., Honn K. V. Lysosomal cathepsin B: Correlation with metastatic potenial. Science. 212:1981;1151-1153.
26. Křepela E., Bártek J., Skalková D., Vicar J., Rasnick D., Taylor-Papadimitriou J., Hallowes R. C. Cytochemical and biochemical evidence of cathepsin B in malignant, transformed and normal breast epithelial cells. J. Cell Sci. 87:1987;145-154.
27. Monsky W. L., Chen W.-T. Proteases of cell adhesion proteins in cancer. Cancer Biol. 4:1993;251-258.
28. Monsky W. L., Lin C.-Y., Aoyama A., Kelly T., Akiyama S. K., Mueller S. C., Chen W.-T. A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res. 54:1994;5702-5710.
29. Lah T. T., Calaf G., Kalman E., Shinde B. G., Russo J., Jarosz D., Zabrecky J., Somers R., Daskal I. Cathepsins D, B and L in breast carcinoma and in transformed human breast epithelial cells (HBEC). Biol. Chem. Hoppe-Seyler. 376:1995;357-363.
30. Chen W.-T. Proteases associated with invadopodia, and their role in degradation of extracellular matrix. Enzyme Protein. 49:1996;59-71.
31. Andreasen P. A., Kjøller L., Christensen L., Duffy M. J. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int. J. Cancer. 72:1997;1-22.
32. Pöllänen J., Saksela O., Salonen E.-M., Andreasen P., Nielsen L., Danø K., Vaheri A. Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J. Cell Biol. 104:1987;1085-1096.
33. Pöllänen J., Hedman K., Nielsen L. S., Danø K., Vaheri A. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J. Cell Biol. 106:1988;87-95.
34. Hébert C. A., Baker J. B. Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: Colocalization of cell surface urokinase with vinculin. J. Cell Biol. 106:1988;1241-1247.
35. Nakajima M., Irimura T., Di Ferrante D., Di Ferrante N., Nicolson G. L. Heparan sulfate degradation: Relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science. 220:1983;611-613.
36. Chen W.-T., Olden K., Bernard B. A., Chu F.-F. Expression of transformation-associated protease(s) that degrade fibronectin at cell contact sites. J. Cell Biol. 98:1984;1546-1555.
37. Chen J.-M., Chen W.-T. Fibronectin-degrading proteases from the membranes of transformed cells. Cell. 48:1987;193-203.
38. Lah T. T., Buck M. R., Honn K. V., Crissman J. D., Rao N. C., Liotta L. A., Sloane B. F. Degradation of laminin by human tumor cathepsin B. Clin. Exp. Metastasis. 7:1989;461-468.
39. Heck L. W., Blackburn W. D., Irwin M. H., Abrahamson D. R. Degradation of basement membrane laminin by human neutrophil elastase and cathepsin G. Am. J. Pathol. 136:1990;1267-1274.
40. Boyd D. Plasminogen dependent laminin degradation and matrigel invasion by cultured colon cancer is directed by receptor-bound urokinase. Fibrinolysis. 6:1992;17-21.
41. Marchina E., De Petro G., Barlati S. Interaction of tissue-type plasminogen activator with fibronectin and fibronectin fragments. Fibrinolysis. 7:1993;51-57.
42. von Bredow D. C., Nagle R. B., Bowden G. T., Cress A. E. Degradation of fibronectin fibrils by matrilysin and characterization of the degradation products. Exp. Cell Res. 221:1995;83-91.
43. Owen C. A., Campbell E. J. Neutrophil proteinases and matrix degradation: The cell biology of pericellular proteolysis. Semin. Cell Biol. 6:1995;367-376.
44. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol. 7:1995;728-735.
45. Ossowski L., Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell. 35:1983;611-619.
46. Monard D. Role of protease inhibition in cellular migration and neuritic outgrowth. Biochem. Pharmacol. 36:1987;1389-1392.
47. Alizadeh H., Ma D., Berman M., Bellingham D., Comerford S. A., Gething M.-J. H., Sambrook J. F., Niederkorn J. Y. Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. Curr. Eye Res. 14:1995;449-458.
48. Kawada M., Umezawa K. Suppression of in vitro invasion of human fibrosarcoma cells by a leupeptin analogue inhibiting the urokinase-plasmin system. Biochem. Biophys. Res. Commun. 209:1995;25-30.
49. Kobayashi H., Gotoh J., Shinohara H., Moniwa N., Terao T. Inhibition of metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb. Haemostas. 71:1994;474-480.
50. Watson S. A., Morris T. M., Robinson G., Crimmin M. J., Brown P. D., Hardcastle J. D. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res. 55:1995;3629-3633.
51. Wilhelm O., Sxhmitt M., Höhl S., Senekowitsch R., Graeff H. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin. Exp. Metastasis. 13:1995;296-302.
52. Wei Y., Waltz D. A., Rao N., Drummond R. J., Rosenberg S., Chapman H. A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269:1994;32380-32388.
53. Kanse S. M., Kost C., Wilhelm O. G., Andreasen P. A., Preissner K. T. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res. 224:1996;344-353.
54. Yebra M., Parry G. C. N., Strömblad S., Mackman N., Rosenberg S., Mueller B. M., Cheresh D. A. Requirement of receptor-bound urokinase-type plasminogen activator for integrin αvβ5-directed cell migration. J. Biol. Chem. 271:1996;29393-29399.
55. v3. Nature. 383:1996;441-443.
56. Kjøller L., Kanse S. M., Kirkegaard T., Rodenburg K. W., Rønne E., Goodman S. L., Preissner K. T., Ossowski L., Andreasen P. A. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp. Cell Res. 232:1997;420-429.
57. Gordon S. R. Cytological and immunocytochemical approaches to the study of corneal endothelial wound repair. Prog. Histochem. Cytochem. 28:1994;1-66.
58. Goldman R. Ion distribution and membrane permeability in lysosomal suspensions. Lysosomes in Biology and Pathology. 1976;North Holland, Amsterdam.
59. Gomori G. Histochemical methods for acid phosphatase. J. Histochem. Cytochem. 4:1956;453-461.
60. Basbaum C. B., Werb Z. Focalized proteolysis: Spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr. Opin. Cell Biol. 8:1996;731-738.
61. Saarialho-Kere U. K., Kovacs S. O., Pentland A. P., Olerud J. E., Welgus H. G., Parks W. C. Cell-matrix interactions modulate interstitial collagenase expression by human keratinocytes actively involved in wound healing. J. Clin. Invest. 92:1993;2858-2866.
62. Salo T., Mäkela M., Kylmäniemi M., Autio-Harmainen H., Larjava H. Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab. Invest. 70:1994;176-182.
63. Holtzman E. Lysosomes: A survey. Alfert M., Beermann W., Rudkin G., Sandritter W., Sitte P. Cell Biology Monographs. 1976;Springer-Verlag, Vienna.
64. Mellman I., Fuchs R., Helenius A. Acidification of the endocytic and exocytic pathways. Annu. Rev. Biochem. 55:1986;663-700.
65. Graf M., Baici A., Sträuli P. Histochemical localization of cathepsin B at the invasion front of the rabbit V2 carcinoma. Lab. Invest. 45:1981;587-596.
66. Leto G., Gebbia N., Rausa L., Tumminello F. M. Cathepsin D in the malignant progression of neoplastic diseases (Review). Anticancer Res. 12:1992;235-240.
67. Rempel S. A., Rosenblum M. L., Mikkelsen T., Yan P.-S., Ellis K. D., Golembieski W. A., Sameni M., Rozhin J., Ziegler G., Sloane B. F. Cathepsin B expression and localization in glioma progression and invasion. Cancer Res. 54:1994;6027-6031.
68. Tripathi R. C., Tripathi B. J., Park J. K. Localization of urokinase-type plasminogen activator in human eyes: An immunocytochemical study. Exp. Eye Res. 51:1990;545-552.
69. Ossowski L., Quigley J. P., Reich E. Plasminogen, a necessary factor for cell migration in vitro. Reich E., Rifkin D. B., Shaw E. Proteases and Biological Control. 1975;Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
70. Wijnberg M. J., Nieuwenbroek N. M. E., Slomp J., Quax P. H. A., Verheijen J. H. Urokinase and tissue-type plasminogen activator stimulate human vascular smooth muscle cell migration. Fibrinolysis. 10:1996;75-78.
71. Bastholm L., Nielsen M. H., DeMay J., Danø K., Brünner N., Høyer-Hansen G., Rønne E., Elling F. Confocal fluorescence microscopy of urokinase plasminogen activator receptor and cathepsin D in human MDA-MB-231 breast cancer cells migrating in reconstituted basement membrane. Biotechnol. Histochem. 69:1994;61-67.
72. McNeill H., Jensen P. J. A high affinity receptor for urokinase plasminogen activator on human keratinocytes: Characterization and potential modulation during migration. Cell Regul. 1:1990;843-852.
73. Okada S. S., Tomaszewski J. E., Barnathan E. S. Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro. Exp. Cell Res. 217:1995;180-187.
74. Bayraktutan U., Jones P. Expression of the human gene encoding urokinase plasminogen activator is activated by disruption of the cytoskeleton. Exp. Cell Res. 221:1995;486-495.
75. Gordon S. R., Essner E., Rothstein H. In situ demonstration of actin in normal and injured ocular tissues using 7-nitrobenz-2-oxa-1,3-diazole phallacidin. Cell Motil. 2:1982;343-354.
76. Morton K., Hutchinson C., Jeanny J. C., Karpouzas I., Pouliquen Y., Courtois Y. Colocalization of fibroblast growth factor binding sites with extracellular matrix components in normal and keratoconus corneas. Curr. Eye Res. 8:1989;975-987.
77. Folkman J., Klagsbrun M., Sasse J., Wadzinski M., Ingber D., Vlodavsky I. A heparin-binding angiogenic protein - basic fibroblast growth factor - is stored within basement membrane. Am. J. Pathol. 130:1988;393-400.
78. Presta M., Maier J. A. M., Rusnati M., Ragnotti G. Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. J. Cell. Physiol. 140:1989;68-74.
79. Briozzo P., Badet J., Capony F., Pieri I., Montcourrier P., Barritault D., Rochefort H. MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: A permissive role for cathepsin D. Exp. Cell Res. 194:1991;252-259.
80. Falcone D. J., McCaffrey T. A., Haimovitz-Friedman A., Garcia M. Transforming growth factor-β1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor. J. Cell. Physiol. 155:1993;595-605.
81. Rochefort H. Biological and clinical significance of cathepsin D in breast cancer. Acta Oncol. 31:1992;125-130.